Yazar "Tuna, Ali Kursat" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Efficacy of convalescent plasma therapy in severe COVID-19 patients
    (Pergamon-Elsevier Science Ltd, 2021) Cizmecioglu, Hilal Akay; Goktepe, Mevlut Hakan; Demircioglu, Sinan; Tekinalp, Atakan; Cizmecioglu, Ahmet; Tuna, Ali Kursat; Ozer, Huseyin
    Introduction: The use of convalescent plasma (CP) transfusions is very valuable in the current COVID-19 outbreak, given that there are no specific preventive and therapeutic options. Materials and methods: 50 patients with severe COVID-19 disease treated with convalescent plasma transfusion were included in the study. The efficacy of CP and in which situations it was effective were investigated. Conclusion: 80 % of the patients recovered, and 20 % died in our study. The mean age of the patients who died was found to be higher than the patients who recovered. CRP, ferritin, D-dimer, neutrophil, MPV, and NLR counts were found to be higher, and lymphocyte and platelet counts were lower in the deceased group after CP. It was determined that patients who received CP within the first five days were hospitalized for a shorter period. Discussion: Administration of CP transfusion within the first five days in severe COVID-19 patients has been shown to reduce hospital stay length.
  • Küçük Resim Yok
    Öğe
    Might periostin serve as a marker of bone marrow involvement in patients with diffuse large B-cell lymphoma?
    (Walter De Gruyter Gmbh, 2022) Tekinalp, Atakan; Kars, Taha Ulutan; Tuna, Ali Kursat; Kilinc, Ibrahim; Demircioglu, Sinan; Ceneli, Ozcan
    Objectives We measured the serum periostin levels in patients with DLBCL and determined whether the levels reflected the clinical findings. Methods This was a case-control study. DLBCL patients diagnosed between March 2021 and October 2021 (n=36) and healthy volunteers (n=36) (Control group) were included. The serum periostin levels of the two groups were compared. Moreover, subgroup analyses were conducted in the patient group. Results The serum periostin level was significantly higher in the patient than the control group (28.8 +/- 3.2 vs. 15.1 +/- 7.5 ng/mL, p=0.017). On subgroup analyses, the median serum periostin level of nine (25%) patients with bone marrow involvement was higher than that of the 27 (75%) lacking bone marrow involvement (12.7 vs. 21.7 ng/mL, p=0.018). On ROC analysis, the optimal periostin cutoff for bone marrow involvement was 17.3 ng/mL (sensitivity 77%, specificity 67%, AUC 0.765; 95% CI; 0.606-0.924, p=0.018). By the disease stage, the periostin level was higher in stage 4 patients than in those of other stages (21.3 vs. 12.0 ng/mL, p=0.029). Conclusions The periostin level correlated with such involvement; periostin may serve as a novel prognostic marker of DLBCL.
  • Küçük Resim Yok
    Öğe
    Might periostin serve as a marker of bone marrow involvement in patients with diffuse large B-cell lymphoma?
    (Walter De Gruyter Gmbh, 2022) Tekinalp, Atakan; Kars, Taha Ulutan; Tuna, Ali Kursat; Kilinc, Ibrahim; Demircioglu, Sinan; Ceneli, Ozcan
    Objectives We measured the serum periostin levels in patients with DLBCL and determined whether the levels reflected the clinical findings. Methods This was a case-control study. DLBCL patients diagnosed between March 2021 and October 2021 (n=36) and healthy volunteers (n=36) (Control group) were included. The serum periostin levels of the two groups were compared. Moreover, subgroup analyses were conducted in the patient group. Results The serum periostin level was significantly higher in the patient than the control group (28.8 +/- 3.2 vs. 15.1 +/- 7.5 ng/mL, p=0.017). On subgroup analyses, the median serum periostin level of nine (25%) patients with bone marrow involvement was higher than that of the 27 (75%) lacking bone marrow involvement (12.7 vs. 21.7 ng/mL, p=0.018). On ROC analysis, the optimal periostin cutoff for bone marrow involvement was 17.3 ng/mL (sensitivity 77%, specificity 67%, AUC 0.765; 95% CI; 0.606-0.924, p=0.018). By the disease stage, the periostin level was higher in stage 4 patients than in those of other stages (21.3 vs. 12.0 ng/mL, p=0.029). Conclusions The periostin level correlated with such involvement; periostin may serve as a novel prognostic marker of DLBCL.